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Psoriasis as a manifestation of HIV-related
immune reconstitution inflammatory
syndrome
To the Editor: Immune reconstitution inflammatory
syndrome (IRIS) is a paradoxical exacerbation of a
pre-existing condition or emergence of a previously
unknown disease occurring in an HIV-infected
patient after initiating combined antiretroviral ther-
apy (cART). IRIS begins days to months after starting
cART, and is associated with decreasing viral load.1
The skin accounts for 52% to 78% of presentations,
including a range of infectious, inflammatory, and
neoplastic conditions.2 Inflammatory dermatoses
such as eosinophilic folliculitis, seborrhea, and acne
vulgaris have all been reported.3,4 Here we present,
to our knowledge, the first report of paradoxical
worsening of psoriasis as a presentation of IRIS.
A 63-year-old man with type 2 diabetes mellitus,
hypertension, hepatitis C, HIV diagnosed in 1997,
and a history of mild, untreated less than 1% total
body surface area psoriasis presented to derma-
tology 1 month after starting a new cART, Stribild
(elvitegravir, tenofovir, cobicistat, emtricitabine).
The patient was switched 1 month prior from his
previous cART regimen of Truvada (emtricitabine
and tenofovir disoproxil fumarate), darunavir, and
ritonavir, to Stribild, a once-a-day cART, because
of concerns of medication noncompliance. His
most recent CD4 count, 5 months before presenta-
tion, was 204 cells/L and his viral load was
177,857 copies/mL. Skin examination demonstrated
confluent erythema, edema, and focal areas of
platelike desquamation over the palmar surfaces
of both hands; thick sharply demarcated plaques
with silvery scale over the elbows; and an erythem-
atous patch over the sacrum, with sparing of the
feet and nails, affecting approximately 10% total
body surface area. Despite reports of mild joint
stiffness in his hands, plain film x-rays did notOpen access under CC BY-NC-ND license.show signs of psoriatic arthritis. A repeated CD4
count was 138 cell/L and viral load was 257
copies/mL. He met the proposed diagnostic criteria
for IRIS, with worsening of a pre-existing condition
( psoriasis) and a concomitant greater than log 10
reduction in viral load.5 He was started on topical
psoralen plus ultraviolet A light 3 times per week
and clobetasol ointment 0.05% twice daily, with
improvement over the course of 2 months, even-
tually returning to less than 1% affected total body
surface area. Of interest, 1 week before worsening
psoriasis, he also developed herpes zoster
involving the right leg and buttock, which was
resolving at the time of his initial presentation to
dermatology.
At the 12th World AIDS Conference in Geneva
in 1999, French et al6 reported numerous condi-
tions worsening after starting cART and introduced
the term ‘‘immune restoration disease,’’ which is
now more commonly termed ‘‘immune reconstitu-
tion inflammatory syndrome.’’ Over 15 years after
the first reports, IRIS remains a well-described
but poorly understood phenomenon. There is
emerging evidence that one of the immunopatho-
genic mechanisms of IRIS involves the rapid
and dysregulated shift from the T helper (Th)2-
predominant state of advanced HIV infection to
the Th1- and Th17-dominant state of immune
recovery. It is intriguing that psoriasis, a Th1- and
Th17-mediated inflammatory condition, has not, to
our knowledge, until now been reported to
undergo an IRIS reaction, despite being a relatively
common HIV-associated dermatosis.
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Fig 1. Isotopic response of granulomatous rosacea at a
site of prior herpes simplex infection. Primary lesion.
Initial presentation of a mildly indurated, erythematous
plaque with central yellow crusting located on medial
aspect of forehead after a resolved herpes simplex virus
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antiretroviral therapy. HIV Med 2000;1:107-15.infection.http://dx.doi.org/10.1016/j.jaad.2014.09.032Fig 2. Histopathology of granulomatous rosacea occur-
ring as isotopic response. Punch biopsy specimen of
erythematous plaque revealing superficial granulomatous
inflammation with giant cells (arrow), with a superficial
and deep lymphohistiocytic infiltrate. Viral cytopathic
effect is not identified. (Hematoxylin-eosin stain; original
magnification: 320.)Granulomatous rosacea manifesting after
herpes simplex 2 infection: A case of Wolf’s
isotopic response
To the Editor: We present the case of a 57-year-old
man with a 2-year history of a recurrent transient
eruption on the mid aspect of his forehead,
described as pruritic, erythematous vesicles
preceded by a tingling sensation. He had previously
been treated with valacyclovir with modest
response. On presentation to our clinic, he had a
mildly indurated erythematous plaque across the
mid aspect of his forehead, with a small yellow
crusted plaque in the center (Fig 1). He reported that
the crusted plaque appeared approximately 1 year
prior, after an episode of vesicular eruptions
resolved in the same location. He also endorsed
the plaque worsening with heat and exercise.
Histologic examination of a punch biopsy specimen
of the lesion showed granulomatous dermatitis,
consistent with granulomatous rosacea (Fig 2),
with negative immunohistochemical staining for
herpes simplex virus and varicella zoster virus. He
was given a diagnosis of granulomatous rosacea
and empirically prescribed oral doxycycline and
topical metronidazole for a total of 10 weeks. At 10
weeks he had improved significantly, with near
clearance of the erythematous plaque. Within
months of the patient’s diagnosis of granulomatous
rosacea, he presented with another recurrence of the
vesicular eruption, at which time culture and direct
fluorescent antibody test confirmed herpes simplex
virus 2.
To our knowledge and after extensive literature
searching in MEDLINE (PubMed), Embase, and the
Web of Science databases for published English-
language articles, this is the first report of a case of
granulomatous rosacea arising at the site of arecurrent herpes simplex eruption, consistent with
Wolf’s isotopic response.
When considering the pathogenic mechanism
driving the isotopic response, 4 causes have been
described: viral, immunologic, vascular, and neural.1
Although the primary lesion in our patient was
viral, there was no evidence of viral infection on
histopathology of the secondary lesion. A better
explanation may lie in the immunologic, vascular,
or neural theories.
Alterations in cutaneous vascular homeostasis
have been implicated in the origin of rosacea,2 and
indeed it has been theorized that microcirculation
may be altered by local infiltration of primary inflam-
matory factors such as those seen in viral infection.3
The neural origin theory proposes that the destruc-
tion of nerve fibers may affect the local immune
response, sometimes leading to up-regulation of
growth factors and resulting in the promotion of
